Wedbush Reiterates Outperform on Scholar Rock Holding, Maintains $58 Price Target
Scholar Rock Holding Corp SRRK
$47.30
▼ -3.46%
($-1.70)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$49.04
Prev Close
$48.99
Day Range
$46.92 – $49.33
52W Range
$27.07 – $58.49
Market Cap
$5.67B
Beta
0.65
EPS (TTM)
$-3.45
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2018-05-24 |
| Shares Out. | 119,830,000 |
| Website | scholarrock.com/ ↗ |
| Phone | 13026587581 |
| Employees | 289 |
| Net Income | -$105.5M |
| Free Cash Flow | -$303.9M |
| Total Assets | $535.3M |
| Total Liabilities | $259.2M |
| Equity | $276.0M |
About Scholar Rock Holding Corp
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Scholar Rock Holding Corp is a publicly traded company under the ticker symbol SRRK on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
24 analysts (2026-07-01)